Can you take Ixabepilone with Natalizumab?

Ixabepilone has a moderate potential interaction with Arrhythmia.

The use of ixabepilone in combination with capecitabine may increase cardiac adverse reactions, such as myocardial ischemia and ventricular dysfunction. Care should be exercised when using this agent in combination with capecitabine in patients with a history of cardiac disease. It is recommended to discontinue treatment in patients who develop cardiac ischemia or impaired cardiac function.

Ixabepilone has a moderate potential interaction with Cardiovascular Conditions and Disorders.

The use of ixabepilone in combination with capecitabine may increase cardiac adverse reactions, such as myocardial ischemia and ventricular dysfunction. Care should be exercised when using this agent in combination with capecitabine in patients with a history of cardiac disease. It is recommended to discontinue treatment in patients who develop cardiac ischemia or impaired cardiac function.

Ixabepilone has a moderate potential interaction with Diabetes Mellitus.

The use of ixabepilone in combination with capecitabine may cause peripheral neuropathy. Patients treated with ixabepilone in combination with capecitabine should be monitored for symptoms of neuropathy. Patients experiencing new or worsening symptoms may require a reduction or delay in the dose. Caution should be used when treating patients with diabetes mellitus or preexisting peripheral neuropathy.

Natalizumab has a moderate potential interaction with Herpes Zoster Meningitis.

Natalizumab increases the risk of developing encephalitis and meningitis caused by herpes simplex and varicella zoster viruses. It is recommended to monitor patients receiving natalizumab for signs and symptoms of meningitis and encephalitis. If herpes encephalitis or meningitis occurs, treatment should be discontinued, and appropriate treatment for herpes encephalitis/meningitis should be administered.

Ixabepilone has a major potential interaction with Hyperbilirubinemia.

The use of ixabepilone in combination with capecitabine is contraindicated in patients with AST or ALT >2.5 x ULN or bilirubin >1 x ULN due to increased risk of toxicity and neutropenia-related death.

Ixabepilone has a major potential interaction with Immunodeficiency.

Ixabepilone is contraindicated in patients who have a neutrophil count <1500 cells/mm3 or a platelet count <100,000 cells/mm3.

Natalizumab has a major potential interaction with Immunodeficiency.

Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML). Certain agents are contraindicated in patients who have or have had PML. Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents. Health care professionals should monitor patients for any new sign or symptom suggestive of PML. Therapy dosing should be withheld immediately and an appropriate diagnostic evaluation should be performed at the first sign or symptom suggestive of PML.

Natalizumab has a major potential interaction with Infection.

Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents. Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections. Caution should be exercised when considering their use in patients with severe or chronic infections. It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.

Ixabepilone has a moderate potential interaction with Ischemic Heart Disease.

The use of ixabepilone in combination with capecitabine may increase cardiac adverse reactions, such as myocardial ischemia and ventricular dysfunction. Care should be exercised when using this agent in combination with capecitabine in patients with a history of cardiac disease. It is recommended to discontinue treatment in patients who develop cardiac ischemia or impaired cardiac function.

Ixabepilone has a major potential interaction with Liver Disease.

The use of ixabepilone in combination with capecitabine is contraindicated in patients with AST or ALT >2.5 x ULN or bilirubin >1 x ULN due to increased risk of toxicity and neutropenia-related death.

Natalizumab has a moderate potential interaction with Liver Disease.

Postmarketing reports have associated the use of natalizumab with severe hepatic toxicity, including acute liver failure requiring transplant. Natalizumab should be discontinued in patients with jaundice or other evidence of significant liver injury and appropriate therapy should be instituted according to clinical guidelines.

Ixabepilone has a major potential interaction with Neutropenia.

Ixabepilone is contraindicated in patients who have a neutrophil count <1500 cells/mm3 or a platelet count <100,000 cells/mm3.

Ixabepilone has a moderate potential interaction with Peripheral Neuropathy.

The use of ixabepilone in combination with capecitabine may cause peripheral neuropathy. Patients treated with ixabepilone in combination with capecitabine should be monitored for symptoms of neuropathy. Patients experiencing new or worsening symptoms may require a reduction or delay in the dose. Caution should be used when treating patients with diabetes mellitus or preexisting peripheral neuropathy.

Ixabepilone has a major potential interaction with Thrombocytopenia.

Ixabepilone is contraindicated in patients who have a neutrophil count <1500 cells/mm3 or a platelet count <100,000 cells/mm3.